Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term clinical data on patient outcomes.

EP: 1.The Role of Rectal Spacers in Patients Undergoing Radiation Therapy for Prostate Cancer

EP: 2.Common Adverse Effects in Patients With Prostate Cancer Undergoing Radiation Therapy

Now Viewing

EP: 3.Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy

EP: 4.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on SpaceOAR and SpaceOAR Vue

EP: 5.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect

EP: 6.Impact of Rectal Spacers on Sexual Quality-of-Life After Radiotherapy in Patients With Prostate Cancer

EP: 7.Recommendations for the Use of Rectal Spacers in Clinical Practice for Patients With Prostate Cancer

EP: 8.Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation Therapy

Related Videos

Related Content

Advertisement

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

Related Content

Advertisement

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.